Huang M S, Colby T V, Therneau T M, Daly R C, Gonchoroff N J
Section of Surgical Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Cytometry. 1996 Dec 15;26(4):253-9. doi: 10.1002/(SICI)1097-0320(19961215)26:4<253::AID-CYTO3>3.0.CO;2-D.
Multi-variable flow cytometry studies were done on paraffin-embedded surgical specimens from 97 patients with bronchiolalveolar carcinoma (BAC) and on 10 normal lung tissue specimens to assess the value of nuclear protein content besides DNA ploidy. Tumor tissues were stained for DNA content with propidium iodide and for protein content with fluorescein isothiocyanate. DNA ploidy measurements were successful in 87 of the 97 specimens. Twenty-four (28%) specimens were DNA diploid, and 63 (72%) were DNA nondiploid (DNA tetraploid or DNA aneuploid). There was no significant difference in survival between patients with DNA diploid and with DNA nondiploid tumors (P = 0.69). The protein histogram pattern was bimodal in 26/87 (30%) of patients; these had significantly shorter survival than patients with either normal or right-shift protein histogram patterns (61/87) (P = 0.0033). The nuclear protein measurement was an independent prognostic indicator when corrected for tumor grade and tumor size in a Cox model analysis (P = 0.04). The nuclear protein measurement correlated with nuclear size as determined by nuclear volume measurements. The combination of DNA ploidy, protein, and cell size measurements by flow cytometry provide a useful biologic basis for the variable prognosis seen with BAC tumors.
对97例细支气管肺泡癌（BAC）患者的石蜡包埋手术标本以及10例正常肺组织标本进行了多变量流式细胞术研究，以评估除DNA倍性外核蛋白含量的价值。肿瘤组织用碘化丙啶染色测定DNA含量，用异硫氰酸荧光素染色测定蛋白质含量。97例标本中有87例成功进行了DNA倍性测量。24例（28%）标本为DNA二倍体，63例（72%）为DNA非二倍体（DNA四倍体或DNA非整倍体）。DNA二倍体肿瘤患者和DNA非二倍体肿瘤患者的生存率无显著差异（P = 0.69）。26/87（30%）的患者蛋白质直方图模式为双峰型；这些患者的生存期明显短于蛋白质直方图模式正常或右移的患者（61/87）（P = 0.0033）。在Cox模型分析中，校正肿瘤分级和肿瘤大小后，核蛋白测量是一个独立的预后指标（P = 0.04）。核蛋白测量与通过核体积测量确定的核大小相关。通过流式细胞术对DNA倍性、蛋白质和细胞大小进行测量，为BAC肿瘤所见的不同预后提供了有用的生物学基础。
